Stoke Therapeutics, Inc. STOK Deferred income
Deferred income at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s deferred income?
- Stoke Therapeutics, Inc. (STOK) reported deferred income of $10.07M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s deferred income changed year-over-year?
- Stoke Therapeutics, Inc.'s deferred income decreased by 44.6% year-over-year, from $18.16M to $10.07M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s deferred income?
- Over 3 years (2022 to 2025), Stoke Therapeutics, Inc.'s deferred income has grown at a -7.2% compound annual growth rate (CAGR), from $14.88M to $11.9M.